Barkal et al. found that cancer cells with higher levels of MHC class I proteins or upregulated LILRB1 on tumor-associated macrophages (TAMs) were not responsive to anti-CD47 therapy and had lower levels of phagocytosis (Barkal et al., 2018). This evidence concerns the gene CD47 and cancer.